Company Description
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.
It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety.
Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology.
The company was founded in 2015 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Madan Jagasia |
Contact Details
Address: 1030 Massachusetts Avenue Cambridge, Massachusetts 02138 United States | |
| Phone | (781) 806-6245 |
| Website | obsidiantx.com |
Stock Details
| Ticker Symbol | OBX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Reporting Currency | USD |
| CIK Code | 2130606 |
| CUSIP Number | 67448A106 |
| ISIN Number | US67448A1060 |
Key Executives
| Name | Position |
|---|---|
| Dr. Madan Jagasia M.D., M.S. | President, Chief Executive Officer and Director |
| Dr. Maria Fardis M.B.A., Ph.D. | Executive Chairman of the Board |
| Dana M. Alexander | Chief Technical Officer |
| Dr. Parameswaran Hari M.D., M.S. | Chief Medical Officer |
| Julie B. Feder | Chief Financial Officer |
| Jennifer H. Peterson | Chief People Officer |
| Dr. Peter Barrett Ph.D. | Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 3, 2026 | 8-K | Current Report |
| Aug 3, 2026 | CERT | Certification by an exchange approving securities for listing |
| Aug 3, 2026 | 8-A12B/A | Filing |
| Aug 3, 2026 | 8-A12B | Registration of securities |
| Jul 2, 2026 | EFFECT | Notice of Effectiveness |
| Jul 2, 2026 | 424B3 | Prospectus |
| Jul 2, 2026 | S-4/A | Filing |
| Jun 30, 2026 | S-4/A | Filing |
| Jun 24, 2026 | S-4/A | Filing |